- Email: [email protected]
Abstract: P1207 EFECTS OF ROSA LAEVIGATA MICKX ON RENAL ADVANCED GLYCATION END PRODUCTS AND THEIR RECEPTOR EXPRESSION IN EARLY DIABETIC NEPHROPATHY RATS
Poster - CLINICAL ASPECTS OF CVD - Obesity, Insulin Resistance, and Diabetes Abstract: P1207 Citation: Atherosclerosis Supplement 2009, Vol. 10, Issue 2
EFECTS OF ROSA LAEVIGATA MICKX ON RENAL ADVANCED GLYCATION END PRODUCTS AND THEIR RECEPTOR EXPRESSION IN EARLY DIABETIC NEPHROPATHY RATS Y Zhou, Q Liao, Q Zhang 1
Department of Biochemistry and Molecular Biology and Department of Clinical Nursing, University of South China, Hengyang, Hunan; 2Department of Pathology, University of South China, Hengyang, Hunan Objectives: To investigate the effects and protection mechanism of Rosa Laevigata Mickx on advanced glycation end products(AGEs) and receptor for advanced glycation end products(RAGEs) in early diabetic nephropathies rats and . Methods: The DN model established by a single injection of streptozotocin were randomly divided into 3 groups: model group, Rosa Laevigata Mickx treatment group, irbesartan treatment group, Rosa Laevigata Mickx and irbesartan treatment group. In addition, the normal rats served as control. The urinary protein contents in 24 h, concents of AGEs in the serum and kidney tissues were detected with correlative methods. The expressions of RAGEs and RAGEs mRNA in the kidney tissues were measured by immunohistochemistry and reverse transcription polymerase chain reaction, respectively. The pathological changes of the kidney were also detected under opticmicroscope. Results: In DN rats, Rosa Laevigata Mickx and irbesartan reduced the urinary protein contents in 24 h and the concentrations of AGEs in the serum and kidney tissues, decreased the expressions of RAGEs and RAGEs mRNA in the kidney tissues, and alleviated the morphological damage of kidney remarkably. Furthermore, more satisfactory efect of treatment on DN was observed by the combination of Rosa Laevigata Mickx and irbesartan. Conclusion: Rosa Laevigata Mickx and irbesartan play an equivalent and synergistic role in renal protection against DN by reducing the concentrations of AGEs in the serum and kidney tissues, inhibiting the expressions of RAGEs and RAGEs mRNA in the kidney tissues.
EFECTS OF ROSA LAEVIGATA MICKX ON RENAL ADVANCED GLYCATION END PRODUCTS AND THEIR RECEPTOR EXPRESSION IN EARLY DIABETIC NEPHROPATHY RATS Y Zhou, Q Liao, Q Zhang 1
Department of Biochemistry and Molecular Biology and Department of Clinical Nursing, University of South China, Hengyang, Hunan; 2Department of Pathology, University of South China, Hengyang, Hunan Objectives: To investigate the effects and protection mechanism of Rosa Laevigata Mickx on advanced glycation end products(AGEs) and receptor for advanced glycation end products(RAGEs) in early diabetic nephropathies rats and . Methods: The DN model established by a single injection of streptozotocin were randomly divided into 3 groups: model group, Rosa Laevigata Mickx treatment group, irbesartan treatment group, Rosa Laevigata Mickx and irbesartan treatment group. In addition, the normal rats served as control. The urinary protein contents in 24 h, concents of AGEs in the serum and kidney tissues were detected with correlative methods. The expressions of RAGEs and RAGEs mRNA in the kidney tissues were measured by immunohistochemistry and reverse transcription polymerase chain reaction, respectively. The pathological changes of the kidney were also detected under opticmicroscope. Results: In DN rats, Rosa Laevigata Mickx and irbesartan reduced the urinary protein contents in 24 h and the concentrations of AGEs in the serum and kidney tissues, decreased the expressions of RAGEs and RAGEs mRNA in the kidney tissues, and alleviated the morphological damage of kidney remarkably. Furthermore, more satisfactory efect of treatment on DN was observed by the combination of Rosa Laevigata Mickx and irbesartan. Conclusion: Rosa Laevigata Mickx and irbesartan play an equivalent and synergistic role in renal protection against DN by reducing the concentrations of AGEs in the serum and kidney tissues, inhibiting the expressions of RAGEs and RAGEs mRNA in the kidney tissues.